PTC Therapeutics Inc [PTCT] stock prices are up 0.06% to $34.19 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The PTCT shares have gain 7.62% over the last week, with a monthly amount drifted -4.52%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
PTC Therapeutics Inc [NASDAQ: PTCT] stock has seen the most recent analyst activity on May 20, 2024, when Raymond James upgraded its rating to a Mkt Perform. Previously, Morgan Stanley downgraded its rating to Underweight on December 19, 2023, and kept the price target unchanged to $28. On December 08, 2023, Wells Fargo initiated with a Overweight rating and assigned a price target of $37 on the stock. Oppenheimer upgraded its rating to a Outperform but stick to its price target of $165 on October 30, 2023. Citigroup downgraded its rating to a Sell and reduced its price target to $17 on October 27, 2023. Truist downgraded its rating to Hold for this stock on October 06, 2023, and downed its price target to $25. In a note dated September 18, 2023, Citigroup downgraded an Neutral rating on this stock and revised its target price from $55 to $28.
The stock price of PTC Therapeutics Inc [PTCT] has been fluctuating between $17.53 and $42.14 over the past year. Currently, Wall Street analysts expect the stock to reach $44 within the next 12 months. PTC Therapeutics Inc [NASDAQ: PTCT] shares were valued at $34.19 at the most recent close of the market. An investor can expect a potential return of 28.69% based on the average PTCT price forecast.
Analyzing the PTCT fundamentals
The PTC Therapeutics Inc [NASDAQ:PTCT] reported sales of 927.56M for trailing twelve months, representing a drop of -4.66%. Gross Profit Margin for this corporation currently stands at 0.79% with Operating Profit Margin at -0.4%, Pretax Profit Margin comes in at -0.7%, and Net Profit Margin reading is -0.62%. To continue investigating profitability, this company’s Return on Assets is posted at -0.32, Equity is 0.78 and Total Capital is -0.3. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-0.34.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 33.52 points at the first support level, and at 32.84 for the second support level. However, for the 1st resistance point, the stock is sitting at 34.71, and for the 2nd resistance point, it is at 35.23.
Ratios To Look Out For
It’s worth pointing out that PTC Therapeutics Inc [NASDAQ:PTCT]’s Current Ratio is 2.03. In addition, the Quick Ratio stands at 1.98 and the Cash Ratio stands at 0.95. Considering the valuation of this stock, the price to sales ratio is 2.83.
Transactions by insiders
Recent insider trading involved ZELDIS JEROME B, Director, that happened on May 22 ’24 when 20000.0 shares were sold. EVP & CHIEF MEDICAL OFFICER, Golden Lee Scott completed a deal on May 07 ’24 to sell 175.0 shares. Meanwhile, CHIEF EXECUTIVE OFFICER Klein Matthew B. sold 3361.0 shares on Apr 19 ’24.
